Renal cell carcinoma
Not recruitingStudy of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment
Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment
- Disease:Renal cell carcinoma
- Substances:BelzutifanCabozantinib+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Belzutifan
- Sponsor:Merck Sharp & Dohme LLC









